Horizon Pharma

Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland.
Ballsbridge, IE
Size (employees)
1,050 (est)+40%
Horizon Pharma was founded in 2008 and is headquartered in Ballsbridge, IE

Key People at Horizon Pharma

Jeffrey D. Kent

Jeffrey D. Kent

Senior Vice President, Medical Affairs & Outcomes Research
Brian Beeler

Brian Beeler

Chief Compliance Officer and Vice President, Associate General Counsel
Amy Grahn

Amy Grahn

Senior Vice President, Clinical Development and Operations
Robert De Vaere

Robert De Vaere

Executive Vice President and Chief Financial Officer
Ben Bove

Ben Bove

Senior Vice President, Marketing & Commercial Analytics

Horizon Pharma Office Locations

Horizon Pharma has offices in Ballsbridge, Lake Forest, Mannheim, Reinach and in 2 other locations
Ballsbridge, IE (HQ)
Connaught House Burlington Rd
Chicago, US
3200 150 S Wacker Dr
Roswell, US
270 1000 Holcomb Woods Pkwy
Reinach, CH
17 Kägenstrasse
Mannheim, DE
13 Joseph Meyer Straße
Lake Forest, US
Landmark Of Lake Forest 2 150 S Saunders Rd

Horizon Pharma Data and Metrics

Horizon Pharma Financial Metrics

Horizon Pharma's revenue was reported to be $981.1 m in FY, 2016 which is a 30% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

981.1 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

587.8 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(166.8 m)

EBIT (FY, 2016)

(147.2 m)

Market capitalization (26-May-2017)

1.7 b

Closing share price (26-May-2017)


Cash (31-Dec-2016)

509.1 m
Horizon Pharma's current market capitalization is $1.7 b.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


74 m297 m757 m981.1 m

Revenue growth, %


Cost of goods sold

14.6 m76.8 m219.5 m393.3 m

Gross profit

59.4 m220.2 m537.5 m587.8 m

Gross profit Margin, %


Sales and marketing expense

68.6 m120.3 m220.4 m320.4 m

R&D expense

10.1 m19.4 m41.9 m60.7 m

General and administrative expense

23.6 m89 m219.9 m287.9 m

Operating expense total

102.2 m228.7 m482.2 m735 m


(42.9 m)(8.5 m)55.4 m(147.2 m)

EBIT margin, %


Interest expense

39.2 m23.8 m69.9 m86.6 m

Income tax expense

(1.1 m)(6.1 m)(172.2 m)(61.3 m)

Net Income

(149 m)(263.6 m)39.5 m(166.8 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


80.5 m218.8 m859.6 m509.1 m

Accounts Receivable

16 m78.4 m210.4 m305.7 m


4.9 m14.4 m15.9 m49.6 m

Current Assets

110.8 m329.2 m1.1 b1 b


3.8 m7.2 m14 m23.5 m


253.8 m445.6 m

Total Assets

252.6 m1.1 b3.1 b4.3 b

Accounts Payable

9.9 m21 m16.6 m52.5 m

Current Liabilities

43.3 m215.7 m357.6 m605.9 m

Non-Current Liabilities

258.4 m363 m1.4 b2.4 b

Total Liabilities

301.7 m578.6 m1.8 b3 b

Additional Paid-in Capital

410.4 m1.3 b2 b2.1 b

Retained Earnings

(457.1 m)(720.7 m)(681.2 m)(848 m)

Total Equity

540.2 m1.3 b1.3 b

Financial Leverage

2.1 x2.3 x3.4 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(149 m)(263.6 m)39.5 m(166.8 m)

Depreciation and Amortization

9.3 m34 m138.3 m221.8 m

Accounts Receivable

(12 m)(51 m)(120 m)(67 m)


(3.4 m)7.2 m12.2 m67.6 m

Accounts Payable

3.9 m9.4 m(8.4 m)32.1 m

Cash From Operating Activities

(54.3 m)27.5 m194.2 m369.5 m

Purchases of PP&E

(1.2 m)(3.5 m)(7.2 m)(15.7 m)

Cash From Investing Activities

(36.1 m)(227.7 m)(995 m)(1.4 b)

Cash From Financing Activities

66.7 m338.3 m1.4 b657.1 m

Interest Paid

8.6 m12.4 m42 m60.8 m

Income Taxes Paid

44 k37 k1.9 m22.3 m
Y, 2016

Financial Leverage

3.4 x

Horizon Pharma Market Value History

Horizon Pharma Online and Social Media Presence

Horizon Pharma News and Updates

Horizon Pharma Company Life and Culture

You may also be interested in